About Us

 

ILC Therapeutics™ Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Cancer, Atopic Dermatitis and Psoriasis.

 

Background

 

Innate Lymphoid Cells were discovered 10 years ago and are split into three classes: ILC-1, ILC-2 and ILC-3, each class associated with a different type of disease: Cancer, Atopic Dermatitis and Psoriasis respectively.

 

There is a renaissance of interest in Alpha Interferon driven by the discovery that this protein is the bridge between the two halves of the immune system: the Innate Immune Systems and the Adaptive Immune System. 

 

Our Work

 

For the immune system to reach its full potential in the area of cancer therapy both halves have to be fully engaged. Interest in NK cell therapy is exploding and NK cells are a type of Innate Lymphoid Cell 1 (ILC-1) modulated by alpha interferons. Our hybrid, patented, interferon alpha has been shown to have a powerful stimulatory effect on NK cells and this is critical to maintaining NK cell activity inside tumours where the cancer is trying to switch them off and escape destruction.

 

Our Hybrid 1 has shown modulatory effects on tissue based ILC-2 networks (Atopic Dermatitis) and ILC-3 networks associated with Psoriasis.  

 

All these applications have massive market potential driven by unmet clinical need or under performance of existing therapies. We expect that alone or in combination with current standard of care we have can have a significant clinical impact in the future.


Why Choose Us?

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed eget lacus quis velit viverra iaculis. Interdum et malesuada fames ac ante ipsum primis in faucibus. Vestibulum maximus ipsum ex. Curabitur elementum luctus augue, quis eleifend tortor feugiat vel. Maecenas maximus, ipsum et laoreet congue, diam massa aliquam libero, at pellentesque orci ipsum et velit. Quisque condimentum fermentum tellus at elementum. Morbi in dignissim sapien. Pellentesque interdum sem diam, in mattis lectus hendrerit vel. Nullam nibh diam, fringilla eget ultricies eget, porta eget sem. 

 

Quisque condimentum fermentum tellus at elementum. Morbi in dignissim sapien. Pellentesque interdum sem diam, in mattis lectus hendrerit vel. Nullam nibh diam, fringilla eget ultricies eget, porta eget sem. Praesent vulputate vestibulum felis, viverra interdum diam volutpat non